RecruitingRecruiting
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
NCT05940272 · Memorial Sloan Kettering Cancer Center
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Evaluation of a Communication Intervention (Hematolo-GIST) for Large B-Cell Lymphoma Providers
About this study
The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.
Eligibility criteria
Inclusion Criteria:
Providers
* Currently a an MSK provider caring for patients with DLBCL (including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and treated as large-cell lymphoma)
Patients
* Per medical record, is currently being treated by a provider who is participating in this study (for the purposes of this study, "treating provider" will be defined as any provider who provides care related to the patient's lymphoma diagnosis)
* Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma
* Per medical record, relapse/ refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy or or autologous stem cell transplant (ASCT)
* Self-identify as Black and/or White
* Per medical record, 18 years of age or older
* Per self-report, fluent in English\*\*
* Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:
1. How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
2. What is your preferred language for healthcare? (must respond English)
Exclusion Criteria:
Providers
* Per self-report, planning to leave the cancer center in the next 12 months
Patients
* Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11
* Per research staff judgment and/or self-report, too ill or weak to complete study procedures
* Per medical record or self-report, receiving hospice care at the time of enrollment
Study design
Enrollment target: 48 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2023-07-03
Estimated completion: 2028-07-03
Last updated: 2025-10-09
Interventions
Behavioral: Hematolo-GIST TrainingBehavioral: Participants Appointment
Primary outcomes
- • Feasibility of the Hematolo-GIST intervention among hematologists and participants (Up to 1 year)
Sponsor
Memorial Sloan Kettering Cancer Center · other
Contacts & investigators
ContactKelly McConnell, PhD · contact · McConneK@mskcc.org · 646-888-0026
ContactRevecca Saracino, PhD · contact · jamesr@mskcc.org · 646-888-0263
InvestigatorKelly McConnell, PhD · principal_investigator, Memorial Sloan Kettering Cancer Center
All locations (2)
Memorial Sloan Kettering Cancer Center (All protocol activities)Recruiting
New York, New York, United States
NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only)Not Yet Recruiting
New York, New York, United States